AstraZeneca stock: results due October 30, 2026 ahead of the Xetra open
Published on 10/27/2026 at 07:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUpcoming Results And Analyst View
- AstraZeneca's investor calendar lists 9M and Q3 2026 results for October 30, 2026.
- Barclays maintained a Buy rating on October 26, 2026.
- AstraZeneca stock trades pre-market at EUR 153.63 at 7:39 a.m. CET at Lang & Schwarz on October 27, 2026.
AstraZeneca's investor-relations calendar lists the company's 9M and Q3 2026 results for October 30, 2026. AstraZeneca stock trades pre-market at EUR 153.63 at 7:39 a.m. CET at Lang & Schwarz on October 27, 2026.
Upcoming company results
The company calendar also lists a Meet the Management event at ESMO in Madrid on October 26, 2026, and a Rothschild roadshow in London on November 2, 2026. The 9M and Q3 2026 results are the next dated company event listed on the investor-relations page.
Recent analyst action
Markets Insider reported on October 26, 2026, that Barclays analyst James Gordon maintained a Buy rating on AstraZeneca and set a price target of GBP 160.00. AstraZeneca develops and commercializes prescription medicines across areas including oncology, cardiovascular, renal and metabolic diseases.
Ahead of the Xetra open
The further course from the Xetra open at 9:00 a.m. CET is shown by the continuously updated real-time quote of AstraZeneca stock.
What is on today
The company is a biopharmaceutical business that develops, manufactures and commercializes prescription medicines. Market context: Market report FTSE 100.
